Latest News

Demand for Co.’s Antibiotic Free Animal Feed Is Raising

August 11, 2022 ( Newswire) With consumers moving away from artificial meat products and other preservatives, Avivagen Inc.’s antibiotic free animal feed seems to be just what they’re looking for. With orders coming in and demand raising, expert Clive Maund shares his view on the potential of this life science company.

Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB) is the company that produces antibiotic free animal feed and the demand for its product is improving with the company getting good orders-consumers don’t like artificial meat products and have been rejecting them where they have been tried out.

The one cloud on the horizon for the company of course is the Globalists’ push to eliminate meat for the masses, to be replaced by insects, or nothing or even each other, but that will take time and for now the prospects for the company are improving and of course the globalists will want to continue eating the finest quality meat products themselves even as the proletariat are munching their way through tasty plates of crickets.

They will put this change into effect through the price mechanism, since the masses won’t be able to afford $500 for a piece of steak, but to the globalists this will be chump change.

Following this logic we can see that there will still be a market for the company’s products even if the masses are weaned off meat, since animals will continue being farmed, albeit in much smaller numbers, for the elites who will be happy to pay massively inflated prices.

The outlook for the company is improving. In addition to orders coming in, management has been cleaned up with positive changes and the company is implementing a Smart marketing program and all this together is making it an attractive takeover candidate, given its current low valuation.

Just how cheap the stock is historically can be seen on its long-term 20-year chart below. Way back in 2006 – 2007 the stock price was more than 20 times its current level.

This year it has ground lower and lower, making new lows but the strong Accumulation line implies that a reversal is incubating.

Zooming in somewhat we can see on the 8-year chart the bear market from the 2016 spike top in more detail. It tried to establish a base from the start of 2019 through mid-2021 but then broke lower again into another downleg that took the price to a very low level and this downleg is now believed to have run its course, especially given the continuing strength of the volume indicators-On-balance Volume is shown on this chart.

On the six-month chart we can see recent action in detail. We had earlier expected the obvious line of support at the CA$0.18 level to hold.

It didn’t but the break lower looks like a “head fake” especially given the positive volume pattern and volume indicators.

So this break lower is viewed as an opportunity to add to positions or make fresh purchases at an even better price-it looks like it is very close to breaking back above the CA$0.18 level.

The conclusion is that Avivagen looks like a Strong Buy here for all timeframes on both fundamental and technical grounds. So we stay long and this is a good point to add to positions.

Avivagen Inc website

Avivagen Inc. closed at CA$0.18, $0.135 on August 5, 2022. Disclosures

The above represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund’s opinions are his own, and are not a recommendation or an offer to buy or sell securities. Mr. Maund is an independent analyst who receives no compensation of any kind from any groups, individuals or corporations mentioned in his reports. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund’s opinions on the market and stocks can only be construed as a solicitation to buy and sell securities when they are subject to the prior approval and endorsement of a Registered Securities Advisor operating in accordance with the appropriate regulations in your area of jurisdiction.


1) Clive Maund: I, or members of my immediate household or family, own securities of the following companies mentioned in this article: None. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with: Avivagen Inc. Please click here for more information.

3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.

4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen Inc., a company mentioned in this article.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

More Info:

This news is published on the Newswire – a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:

Health, Wellness and Sustainability Stocks Research and News at – investing ideas for a better world

Like Health, Wellness and Sustainability Stocks? View our LOHAS Stocks Directory

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *